PolyPeptide Group AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPGN.SW research report →
Price Chart
About the company
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies.
- CEO
- Juan Jose Gonzalez
- IPO
- 2021
- Employees
- 1,460
- HQ
- Baar, ZG, CH
Get TickerSpark's AI analysis on PPGN.SW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.45B
- P/E
- 109.34
- Fwd P/E
- 50.28
- PEG
- 0.41
- P/S
- 3.38
- P/B
- 4.41
- EV/EBITDA
- 20.65
- Div Yield
- 0.00%
- Gross Margin
- 22.58%
- Op Margin
- 6.98%
- Net Margin
- 3.15%
- ROE
- 4.17%
- ROIC
- 2.72%
Latest fiscal year · YoY change
- Revenue
- $391.87M+15.7%
- Gross Profit
- $64.32M+63.8%
- Op Income
- $7.41M
- Net Income
- $-21,307,288-8.9%
- EPS
- $-0.64-8.5%
- OCF Growth
- -12.7%
- FCF Growth
- -1352.2%
- 52W High
- $50.10
- 52W Low
- $21.80
- 50D MA
- $43.44
- 200D MA
- $32.71
- Beta
- 1.00
- RSI (14)
- 51
- Avg Volume
- 112.67K
No earnings-call transcripts are available for PPGN.SW yet.
- Free Float
- 39.3%
- Shares Outstanding
- 33.01M
- Float Shares
- 12.96M
Held by 159 ETFs
Biggest fund positions in PPGN.SW by dollar value.
Our PPGN.SW coverage
Recent articles, reports, and earnings notes.
No research on PPGN.SW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PPGN.SW report →Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
gurufocus.com · Jul 19
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
prnewswire.com · Jul 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.